Avivagen Inc. provided update on OxCbeta™ Livestock trial results versus Colistin. The company continues the process of commercializing its nonantibiotic and naturallyoccurring products based on OxCbeta™ Technology that, among their uses, are showing efficacy as a replacement for antibiotics in helping to maintain optimal health and growth in livestock. As previously indicated, OxCbeta™ Livestock has demonstrated efficacy in helping to maintain optimal food animal health and growth without having any antibiotic effects.

For infeed growth promotion and disease prevention for the first month postweaning, as little as 2 partspermillion (2 ppm) of OxCbeta Livestock convincingly outperformed colistin at 100 ppm plus tetracycline at 150 ppm. Further swine trials testing OxCbeta™ Livestock versus colistin are now underway to confirm the reproducibility of such results.